Haematological toxicity compromises MOPP/ABVD chemotherapy in Hodgkin's disease

1991 ◽  
Vol 3 (3) ◽  
pp. 151-154
Author(s):  
M.J. Goodrick ◽  
F. Daniel ◽  
A.G. Prentice ◽  
J.A. Copplestone ◽  
C.J. Tyrrell
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Haematological Toxicity ◽  
Abvd Chemotherapy

scholarly journals Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease

1995 ◽  
Vol 6 (9) ◽  
pp. 895-899 ◽  
Author(s):  
M. Björkholm ◽  
U. Axdorph ◽  
G. Grimfors ◽  
K. Merk ◽  
B. Johansson ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Abvd Chemotherapy

Treatment of 49 Unrandomized Patients with Advanced Hodgkin's Disease

1983 ◽  
Vol 69 (5) ◽  
pp. 463-467
Author(s):  
Teodoro Chisesi ◽  
Orlando Ricciardi ◽  
Sandra Dal Fior ◽  
Francesco Cappellari ◽  
Franco Pozza ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Adjuvant Radiotherapy ◽  
Hodgkin’S Disease ◽  
Treatment Modalities ◽  
Significant Difference ◽  
Involved Field ◽  
Involved Field Radiotherapy ◽  
Abvd Chemotherapy ◽  
Advanced Hodgkin’S Disease

Forty-nine patients with previously untreated advanced Hodgkin's disease were treated in our Institution between 1973 and 1981. Treatment modalities of these patients were reviewed, and they were divided into 3 groups according to the treatment employed: 13 patients received MOPP only, 22 patients received MOPP plus involved field radiotherapy, and 14 received alternating MOPP/ABVD chemotherapy. The response rates for the 3 groups were respectively 38.5%, 63.6% and 78.6%. A longer follow-up is needed to assess a significant difference in survival curves. The advantages of adjuvant radiotherapy and alternating non-cross-resistant drugs in advanced Hodgkin's disease are discussed.

Treatment of Early Clinically Staged Hodgkin's Disease with a Combination of ABVD Chemotherapy Plus Limited Field Radiotherapy

2003 ◽  
Vol 44 (9) ◽  
pp. 1523-1528 ◽  
Author(s):  
T.D. Karmiris ◽  
E. Grigoriou ◽  
M. Tsantekidou ◽  
E. Spanou ◽  
H. Mihalakeas ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Abvd Chemotherapy

Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.

1996 ◽  
Vol 14 (5) ◽  
pp. 1421-1430 ◽  
Author(s):  
S Viviani ◽  
G Bonadonna ◽  
A Santoro ◽  
V Bonfante ◽  
M Zanini ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Half Cycle ◽  
Second Malignancies ◽  
Median Dose ◽  
Bulky Disease ◽  
True Recurrence ◽  
To Receive ◽  
Abvd Chemotherapy ◽  
Advanced Hodgkin’S Disease

PURPOSE To compare, in a prospective randomized trial, the efficacy of two different sequences of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy in untreated advanced Hodgkin's disease. PATIENTS AND METHODS From June 1982 to September 1990, 427 consecutive previously untreated patients with pathologic stage IB, IIA bulky, IIB, III (A and B), and IV (A and B) disease were prospectively randomized to receive two different sequences of MOPP and ABVD for a minimum of six cycles followed by radiotherapy (median dose, 30 Gy) to the nodal site(s) of pretreatment bulky disease. Of 415 assessable patients, 211 received one cycle of MOPP monthly, alternated with one cycle of ABVD (alternating regimen), and 204 patients received one-half cycle of MOPP alternated with one-half cycle of ABVD within a 1-month period (hybrid regimen). RESULTS The complete remission (CR) rate was 91% with the alternating regimen and 89% with the hybrid regimen. At 10 years, the freedom-from-progression (FFP) rate was 67% versus 69% and the overall survival (OS) rate was 74% versus 72%, respectively. After attainment of CR, 85 patients relapsed in nodal (n = 60) versus extranodal with or without nodal (n = 25) sites. In patients given consolidative radiation because of bulky lymphoma, the true recurrence rate was 13%. A total of 23 second malignancies (6%) were documented, including 11 cases of acute nonlymphocytic leukemia. No cases of congestive heart failure attributable to doxorubicin or pulmonary toxicity related to bleomycin were documented. CONCLUSION By delivering MOPP and ABVD, it is possible to cure approximately 70% of patients with advanced Hodgkin's disease. The two different drug sequences yielded superimposable results.

Treatment outcome and pulmonary toxicity of ABVD chemotherapy for Hodgkin’s disease

2002 ◽  
Vol 54 (2) ◽  
pp. 298
Author(s):  
A.K Ng ◽  
M.P Bernardo ◽  
B Silver ◽  
D.C Fisher ◽  
M Stevenson ◽  
...  
Keyword(s):  
Treatment Outcome ◽  
Hodgkin's Disease ◽  
Pulmonary Toxicity ◽  
Hodgkin’S Disease ◽  
Abvd Chemotherapy

Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.

1997 ◽  
Vol 15 (11) ◽  
pp. 3338-3346 ◽  
Author(s):  
D L Longo ◽  
E Glatstein ◽  
P L Duffey ◽  
R C Young ◽  
D C Ihde ◽  
...  
Keyword(s):  
Overall Survival ◽  
Radiation Therapy ◽  
Hodgkin's Disease ◽  
Mediastinal Mass ◽  
Hodgkin’S Disease ◽  
Disease Free Survival ◽  
Free Survival ◽  
Field Radiation ◽  
Disease Free ◽  
Abvd Chemotherapy

PURPOSE To evaluate the efficacy and toxicity of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)/doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy plus mantle-field radiation therapy in the treatment of patients with massive mediastinal Hodgkin's disease of any stage. PATIENTS AND METHODS Eighty patients presented with Hodgkin's disease and a mediastinal mass greater than one third the greatest chest diameter on chest radiograph. Patients were staged and treated with MOPP alternated with ABVD chemotherapy for a total of six cycles. Patients then received 10 Gy mantle-field radiation therapy delivered to the original extent of disease followed by 25 to 35 Gy to the residual abnormalities. RESULTS The complete response (CR) rate was 89%. With a median follow-up duration of 10 years, disease-free survival of the complete responders is 78% at 15 years and overall survival is 75% at 15 years. For patients with stage I or II disease, disease-free survival was 76% at 15 years and overall survival was 79%; for those with stage III or IV disease, disease-free survival was 82% at 15 years and overall survival was 64%. Age, stage, sex, B symptoms, number of extranodal sites, lactate dehydrogenase (LDH) levels, erythrocyte sedimentation rate, and platelet count did not influence treatment outcome. Treatment-related pneumonitis was noted in 16% of patients (fatal in one), mainly in those older than age 35 years who received total doses of radiation therapy greater than 42 Gy. Fertility is more often preserved with MOPP/ABVD therapy than with MOPP chemotherapy and there appears to be less pulmonary and cardiac disease than with ABVD chemotherapy. Two patients have developed second solid tumors within radiation ports and one relapsed patient developed acute leukemia after MOPP salvage therapy. CONCLUSION MOPP/ABVD followed by mantle-field radiation therapy is an effective treatment for all stages of Hodgkin's disease that present with a large mediastinal mass. Our data suggest that the large mediastinal mass is a more dominant determinant of prognosis than Ann Arbor stage or other clinical prognostic factors.

Sign in / Sign up

Export Citation Format

Share Document